Diaceutics (LON:DXRX) Price Target Raised to GBX 215

Diaceutics (LON:DXRX) had its price objective upped by Shore Capital from GBX 180 to GBX 215 in a report issued on Thursday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Diaceutics Price Performance

Shares of LON:DXRX opened at GBX 160 on Thursday. The firm’s 50 day moving average price is GBX 143.93 and its 200-day moving average price is GBX 144.33. Diaceutics has a twelve month low of GBX 106 and a twelve month high of GBX 168. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of £135.40 million, a PE ratio of -88.89 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.